Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 25 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; betadex; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose; lactose monohydrate; croscarmellose sodium; betadex; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 100 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; betadex; lactose monohydrate; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; sodium starch glycollate type a; glucose; purified talc; hypromellose; maize starch; sodium starch glycollate type b; propylene glycol; hyprolose; poloxamer; titanium dioxide; colloidal anhydrous silica; magnesium stearate - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible microorganisms: acute pharyngitis. acute tonsillitis, impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - montelukast sodium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; iron oxide red; magnesium stearate; hyprolose; iron oxide yellow; macrogol 6000; titanium dioxide; lactose monohydrate; microcrystalline cellulose - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; povidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - moxonidine gh is indicated for the treatment of hypertension

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; povidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - moxonidine gh is indicated for the treatment of hypertension

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sevelamer carbonate, quantity: 800 mg - tablet, film coated - excipient ingredients: silicon dioxide; hyprolose; crospovidone; mannitol; zinc stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; purified talc; xanthan gum; polyvinyl alcohol; lecithin - sevelamer lupin is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - montelukast sodium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; iron oxide red; magnesium stearate; hyprolose; iron oxide yellow; macrogol 6000; titanium dioxide; lactose monohydrate; microcrystalline cellulose - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 10.4 mg (equivalent: perampanel, qty 10 mg) - tablet, film coated - excipient ingredients: purified talc; iron oxide yellow; hypromellose; lactose monohydrate; povidone; indigo carmine aluminium lake; macrogol 8000; titanium dioxide; microcrystalline cellulose; magnesium stearate - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.